Live Birth in Woman With Premature Ovarian Insufficiency Receiving Ovarian Administration of Platelet-Rich Plasma (PRP) in Combination With Gonadotropin: A Case Report

Chao-Chin Hsu, Leonard Hsu, Isabel Hsu, Yi-Jen Chiu, Sonam Dorjee, Chao-Chin Hsu, Leonard Hsu, Isabel Hsu, Yi-Jen Chiu, Sonam Dorjee

Abstract

The conception rates among women with premature ovarian insufficiency (POI) remain extremely low. To achieve a successful pregnancy, most of these women have to receive donor oocytes through IVF treatment. Ovarian administration of platelet-rich plasma (PRP) has been recently applied to enhance the ovulatory function in women with poor ovarian response. However, no live birth has been reported for this application in patients with POI. In this study, we present a 37-year-old woman with POI who had secondary amenorrhea for 6 months. The clinical manifestations and evaluation of this women with a diminished ovarian function were an undetectable serum level of AMH (<0.02 ng/mL) and an elevated serum level of FSH (63.65 mIU/mL). A single dose of autologous PRP (extracted from 40 mL of peripheral blood) in combination with gonadotropin (150IU rFSH/75 IU rLH) was directly injected into the stroma of bilateral ovaries via vaginal sonographic guidance. Following the treatment, this patient received controlled ovarian stimulation and IVF during the successive months. Following embryo culture, three cleavage-stage embryos were transferred, leading to a successful pregnancy, which later resulted in the live birth of twins. This case report provides one example of alternative therapy that allows POI patients to use autologous oocytes in IVF treatment.

Keywords: controlled ovarian stimulation (COS); gonadotropin; ovarian administration; platelet-rich plasma (PRP); premature ovarian insufficiency (POI).

Copyright © 2020 Hsu, Hsu, Hsu, Chiu and Dorjee.

References

    1. European Society for Human R Embryology Guideline Group on POI. Webber L, Davies M, Anderson R, Bartlett J, Braat D, et al. . ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. (2016) 31:926–37. 10.1093/humrep/dew027
    1. Aiman J, Smentek C. Premature ovarian failure. Obstet Gynecol. (1985) 66:9–14.
    1. Bidet M, Bachelot A, Bissauge E, Golmard JL, Gricourt S, Dulon J, et al. . Resumption of ovarian function and pregnancies in 358 patients with premature ovarian failure. J Clin Endocrinol Metab. (2011) 96:3864–72. 10.1210/jc.2011-1038
    1. Bachelot A, Nicolas C, Bidet M, Dulon J, Leban M, Golmard JL, et al. . Long-term outcome of ovarian function in women with intermittent premature ovarian insufficiency. Clin Endocrinol. (2017) 86:223–8. 10.1111/cen.13105
    1. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril. (1990) 53:804–10. 10.1016/S0015-0282(16)53513-4
    1. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. (1986) 67:604–6.
    1. Lagergren K, Hammar M, Nedstrand E, Bladh M, Sydsjo G. The prevalence of primary ovarian insufficiency in Sweden; a national register study. BMC Womens Health. (2018) 18:175. 10.1186/s12905-018-0665-2
    1. Wang TR, Yan LY, Yan J, Lu CL, Xia X, Yin TL, et al. . Basic fibroblast growth factor promotes the development of human ovarian early follicles during growth in vitro. Hum Reprod. (2014) 29:568–76. 10.1093/humrep/det465
    1. Hosseini L, Shirazi A, Naderi MM, Shams-Esfandabadi N, Borjian Boroujeni S, Sarvari A, et al. . Platelet-rich plasma promotes the development of isolated human primordial and primary follicles to the preantral stage. Reprod Biomed Online. (2017) 35:343–50. 10.1016/j.rbmo.2017.04.007
    1. Sfakianoudis K, Simopoulou M, Nitsos N, Rapani A, Pappas A, Pantou A, et al. . Autologous platelet-rich plasma treatment enables pregnancy for a woman in premature menopause. J Clin Med. (2018) 8:1. 10.3390/jcm8010001
    1. Sills ES, Rickers NS, Li X, Palermo GD. First data on in vitro fertilization and blastocyst formation after intraovarian injection of calcium gluconate-activated autologous platelet rich plasma. Gynecol Endocrinol. (2018) 34:756–60. 10.1080/09513590.2018.1445219
    1. Sfakianoudis K, Simopoulou M, Nitsos N, Rapani A, Pantou A, Vaxevanoglou T, et al. . A case series on platelet-rich plasma revolutionary management of poor responder patients. Gynecol Obstet Invest. (2019) 84:99–106. 10.1159/000491697
    1. Gougeon A. Human ovarian follicular development: from activation of resting follicles to preovulatory maturation. Ann Endocrinol. (2010) 71:132–43. 10.1016/j.ando.2010.02.021
    1. Oktay K, Briggs D, Gosden RG. Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab. (1997) 82:3748–51. 10.1210/jc.82.11.3748
    1. Allan CM, Wang Y, Jimenez M, Marshan B, Spaliviero J, Illingworth P, et al. . Follicle-stimulating hormone increases primordial follicle reserve in mature female hypogonadal mice. J Endocrinol. (2006) 188:549–57. 10.1677/joe.1.06614
    1. Dhurat R, Sukesh M. Principles and methods of preparation of platelet-rich plasma: a review and author's perspective. J Cutan Aesthet Surg. (2014) 7:189–97. 10.4103/0974-2077.150734
    1. Chahla J, Cinque ME, Piuzzi NS, Mannava S, Geeslin AG, Murray IR, et al. . A call for standardization in platelet-rich plasma preparation protocols and composition reporting: a systematic review of the clinical orthopaedic literature. J Bone Joint Surg Am. (2017) 99:1769–79. 10.2106/JBJS.16.01374
    1. Hsu CC, Hsu CT, Gu Q, Wang ST. Intermittent vaginal injections of gonadotrophins for ovarian stimulation in IVF treatment. Reprod Biomed Online. (2008) 16:617–20. 10.1016/S1472-6483(10)60473-7
    1. Hsu CC, Kuo HC, Hsu CT, Gu Q. The absorption and uptake of recombinant human follicle-stimulating hormone through vaginal subcutaneous injections–a pharmacokinetic study. Reprod Biol Endocrinol. (2009) 7:107. 10.1186/1477-7827-7-107
    1. Bolton VN, Hawes SM, Taylor CT, Parsons JH. Development of spare human preimplantation embryos in vitro: an analysis of the correlations among gross morphology, cleavage rates, and development to the blastocyst. J In Vitro Fert Embryo Transf. (1989) 6:30–5. 10.1007/BF01134578
    1. Pantos K, Nitsos N, Kokkali G, Vaxevanoglou T, Markomichali C, Pantou A, et al., editors. Ovarian rejuvenation and folliculogenesis reactivation in peri-menopausal women after autologous platelet-rich plasma treatment. In: Proceedings of the 32nd Annual Meeting of ESHRE, Helsinki, (2016).
    1. Hsueh AJ, Kawamura K, Cheng Y, Fauser BC. Intraovarian control of early folliculogenesis. Endocr Rev. (2015) 36:1–24. 10.1210/er.2014-1020
    1. Karlsson MO, Wade JR, Loumaye E, Munafo A. The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women. Br J Clin Pharmacol. (1998) 45:13–20. 10.1046/j.1365-2125.1998.00644.x
    1. Rose TH, Roshammar D, Erichsen L, Grundemar L, Ottesen JT. Population pharmacokinetic modelling of FE 999049, a recombinant human follicle-stimulating hormone, in healthy women after single ascending doses. Drugs R D. (2016) 16:173–80. 10.1007/s40268-016-0129-9
    1. Sachdeva K, Upadhyay D, Discutido R, Varghese MM, Albuz F, Almekosh R, et al. . Low gonadotropin dosage reduces aneuploidy in human preimplantation embryos: first clinical study in a UAE population. Genet Test Mol Biomarkers. (2018) 22:630–4. 10.1089/gtmb.2018.0063
    1. Barash OO, Hinckley MD, Rosenbluth EM, Ivani KA, Weckstein LN. High gonadotropin dosage does not affect euploidy and pregnancy rates in IVF PGS cycles with single embryo transfer. Hum Reprod. (2017) 32:2209–17. 10.1093/humrep/dex299
    1. Wu Q, Li H, Zhu Y, Jiang W, Lu J, Wei D, et al. . Dosage of exogenous gonadotropins is not associated with blastocyst aneuploidy or live-birth rates in PGS cycles in Chinese women. Hum Reprod. (2018) 33:1875–82. 10.1093/humrep/dey270
    1. Alper MM, Fauser BC. Ovarian stimulation protocols for IVF: is more better than less? Reprod Biomed Online. (2017) 34:345–53. 10.1016/j.rbmo.2017.01.010
    1. Hsu CC, Kuo HC, Hsu CT, Gu Q. Abdominal mesotherapy injection extended the absorption of follicle-stimulating hormone. Fertil Steril. (2011) 95:2134–6, 2136.e1. 10.1016/j.fertnstert.2010.12.007
    1. Kawamura K, Cheng Y, Suzuki N, Deguchi M, Sato Y, Takae S, et al. . Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci USA. (2013) 110:17474–9. 10.1073/pnas.1312830110
    1. Li J, Kawamura K, Cheng Y, Liu S, Klein C, Liu S, et al. . Activation of dormant ovarian follicles to generate mature eggs. Proc Natl Acad Sci USA. (2010) 107:10280–4. 10.1073/pnas.1001198107
    1. Fraison E, Crawford G, Casper G, Harris V, Ledger W. Pregnancy following diagnosis of premature ovarian insufficiency: a systematic review. Reprod Biomed Online. (2019) 39:467–76. 10.1016/j.rbmo.2019.04.019

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe